Genmab — September 2017

[Bulder]

Tænker på om det mon kan have betydning om checkpoint-proteinet sidder på T-cellen eller på kræftcellen, siden det ser ud til at være PD-1 blokkerne, som mest er under mistanke?

[E_L]

positive or negative depends on how much benefit the PD1 would add to the combo with Dara. And that depends on the disease it is used for. In solid tumours it could be usefull to have the combo i think, in others it hasnt been proven sufficiently
yet?

[Solsen]

Imids går vel ikke i spænd sammen med PD1

[Solsen]

Imids stimulere immunforsvaret på en ikke helt afdækket måde. Så to immunmodullerende stoffer sammen kan være en giftig cocktail.

[Bulder]

Er der nogen, der ved hvad Keytruda-patienten egentlig døde af?

[Bulder]

Omvendt har dara+imid nærmest synergieffekt. Det sås ved dara+pom.

[Solsen]

Mon ikke det er CRS, der er problemet. Vi har dog set at man i CAR-T behandlingen kan mindske de problemer med anti Il-6 behandling. CRS=cytokine release syndrom.

[E_L]

Whatever the problem is, if dara works well enough without PD1 t
he package will be much cheaper...

[Bulder]

Der er en kilometerlang liste over Keytruda's genvordigheder, men en søgning på CRS og cytokine gav ikke hug. http://investors.merck.com/news/press-release-details/2017/Merck-Provides-Further-Update-on-Three-Multiple-Myeloma-Studies-Evaluating-KEYTRUDA-pembrolizumab-in-Combination-with-Pomalidomide-or-Lenalidomide/default.aspx

[Solsen]

https://dev.hematology.org/Thehematologist/Diffusion/7617.aspx Fra et fase 2 Pomalidomider/PD1 forsøg. 40% grade 3-4 SAE.

[Bulder]

vi må afvente den nærmere afklaring

[E_L]

Merck buys Rigontec ; another immuno-oncology combo?
http://www.epvantage.com/Universal/View.aspx?type=Story&id=729882&isEPVantage=yes

[E_L]

meanwhile, the company that had to put Opdivo on partial clinical hold , has some succes with.... Opdivo https://investors.bms.com/iframes/press-releases/press-release-details/2017/CheckMate--214-Study-Evaluating-Opdivo-in-Combination-with-Yervoy-Stopped-Early-for-Demonstrating-Overall-Survival-Benefit-in-Patients-with-Previously-Untreated-Advanced-or-Metastatic-Renal-Cell-Carcinoma/default.aspx

[E_L]

BMY +5% http://www.nasdaq.com/article/bristolmyers-squibb-bmy-has-risen-to-a-new-high-on-phase-3-study-news-20170907-00940

[Sukkeralf]

Thanks E L - thats why Exelixis falls 10%

[Sukkeralf]

Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

(www.fiercebiotech.com)

[Solsen]

At specifik ramme de immunsuppressive T-regs virker mere smart

[tianc]

Sukkeralf -Kan jeg lokke dig til at forklare kort, hvorfor Exel falder på dette?

[Legolas23]

God morn

[bibob]

God morgen.